JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Cryan, J. F.
Right arrow Articles by Lucki, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Cryan, J. F.
Right arrow Articles by Lucki, I.

Vol. 295, Issue 3, 1120-1126, December 2000

Antidepressant-Like Behavioral Effects Mediated by 5-Hydroxytryptamine2C Receptors1

John F. Cryan and Irwin Lucki

Departments of Psychiatry (J.F.C., I.L.) and Pharmacology (I.L.), University of Pennsylvania, Philadelphia, Pennsylvania

The role of the 5-HT2C receptor in mediating active behaviors in the modified rat forced swim test was examined. Three novel selective 5-HT2C receptor agonists, WAY 161503 (0.1-3.0 mg/kg), RO 60-0175 (2-20 mg/kg), and RO 60-0332 (20 mg/kg), all decreased immobility and increased swimming, a pattern of behavior similar to that which occurs with the selective serotonin reuptake inhibitor fluoxetine (5-20 mg/kg). However, the prototypical but nonselective 5-HT2C receptor agonist m-chlorophenylpiperazine (1-10 mg/kg) increased immobility scores in the forced swim test. The selective 5-HT2C receptor antagonist SB 206533 was inactive when given alone (1-20 mg/kg). However, SB 206533 (20 mg/kg) blocked the antidepressant-like effects of both WAY 161503 (1 mg/kg) and fluoxetine (20 mg/kg). The atypical antidepressant (noradrenergic alpha 2 and 5-HT2C receptor antagonist) mianserin reduced immobility and increased climbing at 30 mg/kg. At a behaviorally subactive dose (10 mg/kg), mianserin abolished the effects of WAY 161503 (1 mg/kg) on both swimming and immobility scores. Mianserin blocked the effects of fluoxetine (20 mg/kg) on swimming only; mianserin plus fluoxetine reduced immobility and induced a switch to climbing behavior, suggesting activation of noradrenergic transmission. These data exemplify the benefits of using the modified rat forced swim test, which was sensitive to serotonergic compounds and distinguished behavioral changes associated with serotonergic and noradrenergic effects. Taken together, the results strongly implicate a role for 5-HT2C receptors in the behavioral effects of antidepressant drugs.

1 This research was supported by U.S. Public Heath Service Grant MH 36262.

0022-3565/00/2953-1120$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2000 by The American Society for Pharmacology and Experimental Therapeutics


This article has been cited by other articles:


Home page
 Mol. Biol. CellHome page
M. Labasque, E. Reiter, C. Becamel, J. Bockaert, and P. Marin
Physical Interaction of Calmodulin with the 5-Hydroxytryptamine2C Receptor C-Terminus Is Essential for G Protein-independent, Arrestin-dependent Receptor Signaling
Mol. Biol. Cell, November 1, 2008; 19(11): 4640 - 4650.
[Abstract] [Full Text] [PDF]

Home page
 J. Neurosci.Home page
P. Svenningsson, E. T. Tzavara, H. Qi, R. Carruthers, J. M. Witkin, G. G. Nomikos, and P. Greengard
Biochemical and Behavioral Evidence for Antidepressant-Like Effects of 5-HT6 Receptor Stimulation
J. Neurosci., April 11, 2007; 27(15): 4201 - 4209.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
K. L. Marquis, A. L. Sabb, S. F. Logue, J. A. Brennan, M. J. Piesla, T. A. Comery, S. M. Grauer, C. R. Ashby Jr., H. Q. Nguyen, L. A. Dawson, et al.
WAY-163909 [(7bR,10aR)-1,2,3,4,8,9,10,10a-Octahydro-7bH-cyclopenta-[b][1,4]diazepino[6,7,1hi]indole]: A Novel 5-Hydroxytryptamine 2C Receptor-Selective Agonist with Preclinical Antipsychotic-Like Activity
J. Pharmacol. Exp. Ther., January 1, 2007; 320(1): 486 - 496.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
D. A. Slattery, S. Desrayaud, and J. F. Cryan
GABAB Receptor Antagonist-Mediated Antidepressant-Like Behavior Is Serotonin-Dependent
J. Pharmacol. Exp. Ther., January 1, 2005; 312(1): 290 - 296.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
B. D. Schlag, Z. Lou, M. Fennell, and J. Dunlop
Ligand Dependency of 5-Hydroxytryptamine 2C Receptor Internalization
J. Pharmacol. Exp. Ther., September 1, 2004; 310(3): 865 - 870.
[Abstract] [Full Text] [PDF]

Home page
 J. Pharmacol. Exp. Ther.Home page
A. J. Mayorga, A. Dalvi, M. E. Page, S. Zimov-Levinson, R. Hen, and I. Lucki
Antidepressant-Like Behavioral Effects in 5-Hydroxytryptamine1A and 5-Hydroxytryptamine1B Receptor Mutant Mice
J. Pharmacol. Exp. Ther., September 1, 2001; 298(3): 1101 - 1107.
[Abstract] [Full Text] [PDF]


Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
Molecular Interventions Drug Metabolism and Disposition

Copyright © 2000 by the American Society for Pharmacology and Experimental Therapeutics.